There are over 24 million diagnosed cases of COVID-19 worldwide, with over 800,000 associated deaths. The viral pandemic certainly has people feeling upset, confused, and vulnerable. Unfortunately, some resources are…
Earlier this week, Sarepta Therapeutics announced that the FDA approved a New Drug Application (NDA) for Casimersen (SRP-4045). The treatment, for patients with exon 45 amenable Duchenne muscular dystrophy (DMD),…
According to Charcot-Marie-Tooth News, biotechnology company Helixmith recently began a Phase 1/2a clinical trial to test the efficacy of Engensis (VM202) for patients with Charcot-Marie-Tooth disease type 1A (CMT1A). The…
What do microcephaly, Zika virus, Dengue fever, and COVID-19 have in common? According to a recent press release, HP163 could be a treatment for all four. Developed by biopharmaceutical company…
According to a story from BioSpace, the biotechnology company Tiziana Life Sciences plc has announced that it was recently granted a patent from the United States Patent and Trademark Office…
CohBar has initiated dosing in their Phase 1b trial of CB4211, which is a treatment for nonalcoholic steatohepatitis (NASH). The biotechnology company focuses on mitochondria based therapies with the goal…
Professor Illana Gozes and her team at Tel Aviv University recently developed NAP (CP201). It is an experimental drug that has been proven to be effective in the treatment of…
The importance of potassium restrictions in the diets of chronic kidney disease (CKD) patients has been stressed for years. It lowers levels of serum potassium, therefore lowering the mortality risk.…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
